查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575354

雙標標靶治療市場：按類型、應用、最終用戶、給藥途徑、治療機制分類 - 2025-2030 年全球預測

Dual Targeted Therapy Market by Type (Combination Therapy, Single Drug Therapy), Application (Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases), End User, Drug Administration Route, Therapy Mechanism - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

雙標標靶治療市場2023年估值為2.833億美元，預計2024年將達到3.6128億美元，複合年成長率為26.67%，預計到2030年將達到14.8283億美元。

雙標靶治療是同時使用兩種治療藥物，精確靶向疾病進展中涉及的多種途徑，主要是腫瘤學和自體免疫疾病。與單一療法相比，該策略旨在提高療效、最大限度地減少抗藥性並改善患者的治療結果。對雙標靶治療的需求源於解決單途徑抑制不足的複雜疾病的潛力，例如侵襲性癌症和多方面的自體免疫疾病，它將為該病症提供先進的治療選擇。這些治療方法的應用涵蓋癌症、心血管疾病和感染疾病，最終用途主要在醫院、學術研究機構和生物技術公司。

主要市場統計
基準年[2023] 2.833 億美元
預測年份 [2024] 36128萬美元
預測年份 [2030] 1,482.83百萬美元
複合年成長率（%） 26.67%

雙標靶治療市場受到慢性病的增加、生物技術的進步以及對疾病機制的更好理解等因素的影響。此外，有利的監管環境和研發方面的大量投資正在推動市場成長。醫療需求未滿足的新興市場存在潛在機會，製藥公司和研究機構之間的夥伴關係可以促進管道開發。建議包括專注於個人化醫療方法和利用人工智慧技術來增強藥物發現過程。

然而，它也存在局限性，包括高昂的開發成本、嚴格的監管核准以及複雜的藥物交互作用可能產生的副作用。這些挑戰需要全面的臨床試驗和強力的上市後監測。此外，來自現有療法和生物相似藥的競爭是另一個挑戰。儘管存在這些障礙，創新的成熟領域包括開發新型藥物輸送系統、探索協同效應組合方案以及針對需求未滿足的罕見疾病。

雙標靶治療市場需要一種動態的方法，透過創新和策略聯盟來推動成長並實現突破性治療。鑑於這些治療方法的複雜性，需要對研究和新技術進行持續投資，以克服當前的限制，抓住潛在的機會，並確保市場的持續擴張和成功。

市場動態：揭示快速發展的雙標靶治療市場的關鍵市場洞察

雙標靶治療市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 加強生技公司和學術機構之間的合作，開發新型標靶治療
    • 透過生物技術和基因組學的快速進步提高治療藥物的功效和安全性
    • 改善醫療基礎設施並擴大新興市場的准入範圍將支持治療方法的廣泛使用
    • 增加監管支持以加速突破性治療方法的核准流程
  • 市場限制因素
    • 雙標靶療法的高開發成本和資金籌措障礙
  • 市場機會
    • 罕見疾病和孤兒疾病雙標靶治療的開發
    • 拓展雙標靶治療在癌症領域的應用
    • 將人工智慧和機器學習整合到雙標靶治療的開發中
  • 市場挑戰
    • 雙標靶治療的監管障礙和合規性問題

波特五力：駕馭雙標靶治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解雙標標靶治療市場的外部影響

外部宏觀環境因素在塑造雙標靶治療市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解雙標靶治療市場的競爭格局

對雙標靶治療市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣雙標靶治療市場供應商績效評估

FPNV定位矩陣是評估雙標靶治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了雙標靶治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對雙標靶治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生技公司和學術機構之間不斷加強合作，開發新的標靶治療
      • 生物技術和基因組學的快速進步正在提高治療方法的有效性和安全性
      • 擴大新興市場的醫療基礎設施和准入將推動治療的採用
      • 增加監管支持以加速突破性治療方法的核准流程
    • 抑制因素
      • 雙標靶治療的開發成本高且資金籌措障礙
    • 機會
      • 罕見病疑難病雙標標靶治療進展
      • 擴大雙標靶治療在腫瘤學的應用
      • 將人工智慧和機器學習整合到雙標靶治療的開發中
    • 任務
      • 雙標靶治療的監管障礙和合規性問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章雙重標標靶治療市場：依類型

  • 聯合治療
    • 生物製藥組合
    • 低分子化合物與生物製藥的組合
    • 低分子量化合物的組合
  • 單一療法

第7章雙重標標靶治療市場：依應用分類

  • 自體免疫疾病
    • 多發性硬化症
    • 類風濕性關節炎
  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染
  • 腫瘤學
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 攝護腺癌

第8章雙重標標靶治療市場：依最終用戶分類

  • 醫院
  • 調查機構
  • 專科診所

第9章依藥品管理途徑分類的雙標靶治療市場

  • 肌肉注射
  • 靜脈
  • 口服
  • 皮下的

第10章 雙標標靶治療市場治療機制

  • 免疫療法
  • 標靶治療

第11章美洲雙標標靶治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太雙標標靶治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲雙標標靶治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-546E6FBB3647

The Dual Targeted Therapy Market was valued at USD 283.30 million in 2023, expected to reach USD 361.28 million in 2024, and is projected to grow at a CAGR of 26.67%, to USD 1,482.83 million by 2030.

Dual-targeted therapy involves the simultaneous use of two therapeutic agents that precisely target multiple pathways involved in disease progression, predominantly in oncology and autoimmune disorders. This strategy aims to enhance efficacy, minimize resistance, and improve patient outcomes compared to single-agent therapies. The necessity of dual-targeted therapy arises from its potential to address complex diseases where single-pathway inhibition is insufficient, thereby offering advanced treatment options for conditions like aggressive cancers or multifaceted autoimmune diseases. The application of these therapies extends into oncology, cardiovascular diseases, and infectious diseases, with end-use predominating in hospitals, academic research institutes, and biotechnology companies.

KEY MARKET STATISTICS
Base Year [2023] USD 283.30 million
Estimated Year [2024] USD 361.28 million
Forecast Year [2030] USD 1,482.83 million
CAGR (%) 26.67%

The market for dual-targeted therapy is influenced by factors such as increased prevalence of chronic diseases, advancements in biotechnology, and a growing understanding of disease mechanisms. Furthermore, favorable regulatory landscapes and substantial investments in R&D bolster market growth. Potential opportunities exist in emerging markets with unmet medical needs, and partnerships between pharmaceutical companies and research institutes can expedite pipeline development. Recommendations include focusing on personalized medicine approaches and leveraging AI technologies to enhance drug discovery processes.

However, limitations include high development costs, stringent regulatory approvals, and potential adverse reactions due to complex drug interactions. These challenges necessitate comprehensive clinical trials and robust post-marketing surveillance. Moreover, competition from existing therapies and biosimilars poses additional challenges. Despite these obstacles, areas ripe for innovation include the development of novel drug delivery systems, exploration of synergistic combination regimens, and targeting rare diseases with high unmet needs.

The dual-targeted therapy market demands a dynamic approach, where innovation and strategic alliances can drive growth and enable groundbreaking therapies. Given the intricate nature of these therapies, continuous investment in research and emerging technologies is essential to overcome current limitations and seize potential opportunities, thus ensuring sustained market expansion and success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dual Targeted Therapy Market

The Dual Targeted Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising collaborative efforts between biotech companies and academic institutions to develop novel targeted therapies
    • Rapid advancements in biotechnology and genomics enhancing the efficacy and safety profiles of therapies
    • Expansion of healthcare infrastructure and accessibility in emerging markets boosting therapy uptake
    • Increased regulatory support for fast-tracking the approval process of breakthrough therapies
  • Market Restraints
    • High development costs and financing barriers in dual-targeted therapy treatment
  • Market Opportunities
    • Development of dual targeted therapies for rare and orphan diseases
    • Expansion of dual targeted therapy applications in oncology
    • Integration of AI and machine learning in the development of dual targeted therapies
  • Market Challenges
    • Regulatory hurdles and compliance issues in dual-targeted therapy

Porter's Five Forces: A Strategic Tool for Navigating the Dual Targeted Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dual Targeted Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dual Targeted Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dual Targeted Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dual Targeted Therapy Market

A detailed market share analysis in the Dual Targeted Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dual Targeted Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dual Targeted Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dual Targeted Therapy Market

A strategic analysis of the Dual Targeted Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dual Targeted Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Syndax Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Dual Targeted Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Combination Therapy and Single Drug Therapy. The Combination Therapy is further studied across Biologic Combinations, Small Molecule and Biologic Combinations, and Small Molecule Combinations.
  • Based on Application, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, and Oncology. The Autoimmune Diseases is further studied across Multiple Sclerosis and Rheumatoid Arthritis. The Cardiovascular Diseases is further studied across Coronary Artery Disease, Heart Failure, and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Drug Administration Route, market is studied across Intramuscular, Intravenous, Oral, and Subcutaneous.
  • Based on Therapy Mechanism, market is studied across Immunotherapy and Targeted Therapy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising collaborative efforts between biotech companies and academic institutions to develop novel targeted therapies
      • 5.1.1.2. Rapid advancements in biotechnology and genomics enhancing the efficacy and safety profiles of therapies
      • 5.1.1.3. Expansion of healthcare infrastructure and accessibility in emerging markets boosting therapy uptake
      • 5.1.1.4. Increased regulatory support for fast-tracking the approval process of breakthrough therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and financing barriers in dual-targeted therapy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of dual targeted therapies for rare and orphan diseases
      • 5.1.3.2. Expansion of dual targeted therapy applications in oncology
      • 5.1.3.3. Integration of AI and machine learning in the development of dual targeted therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and compliance issues in dual-targeted therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dual Targeted Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Combination Therapy
    • 6.2.1. Biologic Combinations
    • 6.2.2. Small Molecule and Biologic Combinations
    • 6.2.3. Small Molecule Combinations
  • 6.3. Single Drug Therapy

7. Dual Targeted Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
    • 7.2.1. Multiple Sclerosis
    • 7.2.2. Rheumatoid Arthritis
  • 7.3. Cardiovascular Diseases
    • 7.3.1. Coronary Artery Disease
    • 7.3.2. Heart Failure
    • 7.3.3. Hypertension
  • 7.4. Infectious Diseases
    • 7.4.1. Bacterial Infections
    • 7.4.2. Viral Infections
  • 7.5. Oncology
    • 7.5.1. Breast Cancer
    • 7.5.2. Colorectal Cancer
    • 7.5.3. Lung Cancer
    • 7.5.4. Prostate Cancer

8. Dual Targeted Therapy Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Dual Targeted Therapy Market, by Drug Administration Route

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intravenous
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Dual Targeted Therapy Market, by Therapy Mechanism

  • 10.1. Introduction
  • 10.2. Immunotherapy
  • 10.3. Targeted Therapy

11. Americas Dual Targeted Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dual Targeted Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dual Targeted Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Boehringer Ingelheim International GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Daiichi Sankyo Company, Limited
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Incyte Corporation
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Regeneron Pharmaceuticals, Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. Syndax Pharmaceuticals, Inc.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. DUAL TARGETED THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. DUAL TARGETED THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DUAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DUAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DUAL TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DUAL TARGETED THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BIOLOGIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE AND BIOLOGIC COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SINGLE DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY MECHANISM, 2018-2030 (